GNH USA

Europe — EMA

Korjuny

GNH USA supplies Korjuny (Catumaxomab), a monoclonal antibody for malignant ascites associated with EpCAM‑positive carcinomas.

Catumaxomab

Request sourcing

1
Pack/s

What is Catumaxomab?

Catumaxomab, the active ingredient in Korjuny, is a monoclonal antibody (bispecific/trifunctional) presented as a solution for intraperitoneal infusion for intraperitoneal use. It treats malignant ascites associated with EpCAM‑positive carcinomas in patients with peritoneal tumor burden.

GNH USA supplies Korjuny as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Catumaxomab used for?

Korjuny is indicated for the management of malignant ascites and related peritoneal disease states that express EpCAM.

- Malignant ascites associated with EpCAM‑positive carcinomas: reduces fluid accumulation and improves patient comfort. - Peritoneal carcinomatosis from ovarian carcinoma: helps control tumor burden within the abdominal cavity. - Gastric carcinoma with peritoneal spread: contributes to symptom control and limits disease progression.

What are the side effects of Catumaxomab?

Common Side Effects: - Fever: transient elevation of body temperature after infusion. - Abdominal pain: mild to moderate discomfort in the treated area. - Nausea and vomiting: gastrointestinal upset following administration. - Chills and rigors: shaking sensations during or shortly after infusion. - Fatigue: general tiredness reported by patients. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Hypersensitivity reactions: including rash, urticaria, or anaphylaxis. - Cytokine release syndrome: systemic inflammatory response with fever and hypotension. - Peritonitis: inflammation of the peritoneal lining. - Severe infection: opportunistic infections due to immune modulation. - Hepatic toxicity: elevated liver enzymes or liver injury. - Neutropenia: reduced neutrophil count increasing infection risk.

What precautions apply to Catumaxomab?

Before initiating therapy, clinicians should consider several safety measures.

- Monitor infusion reactions: observe patients during and after infusion for signs of hypersensitivity. - Assess hepatic function: check liver enzymes prior to treatment and periodically thereafter. - Evaluate immune status: be cautious in patients with existing immunosuppression. - Avoid in known hypersensitivity to murine proteins: contraindicated for patients with documented allergy. - Use caution with active infections: defer treatment until infection is controlled. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Catumaxomab interact with?

Catumaxomab may interact with other agents that affect immune function or hemostasis.

Major Interactions (Avoid): - Concurrent use with other immunomodulatory antibodies: risk of additive immune activation. - Live vaccines: may cause uncontrolled infection due to immune suppression. - Cytotoxic chemotherapy: potential for increased toxicity and overlapping adverse effects. - Systemic steroids: may diminish therapeutic efficacy. - High‑dose immunoglobulins: could interfere with antibody binding.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding tendencies. - Antifungal agents metabolized by hepatic pathways: watch for altered drug levels. - NSAIDs: increased risk of gastrointestinal irritation when combined with infusion‑related nausea.

Frequently asked questions

What is Korjuny used for?+
Korjuny is a biologic therapy indicated for the treatment of malignant ascites associated with EpCAM‑positive carcinomas, such as ovarian, gastric, and colorectal cancers. It is used to reduce peritoneal fluid buildup and help control tumor burden within the abdominal cavity.
How does catumaxomab work?+
Catumaxomab is a trifunctional monoclonal antibody that simultaneously binds EpCAM on tumor cells, CD3 on T‑cells, and Fcγ receptors on accessory immune cells. This creates a bridge that activates both adaptive and innate immune responses, leading to targeted destruction of tumor cells in the peritoneal space.
What is the usual dose of Korjuny?+
The dosing regimen for Korjuny is individualized and determined by the prescribing oncologist based on the patient’s clinical condition, tumor type, and treatment protocol. Specific dosage amounts and infusion schedules are not publicly disclosed and should be obtained from the treating physician.
Is Korjuny safe during pregnancy or breastfeeding?+
Safety data for catumaxomab in pregnancy and lactation are limited. Because the drug can affect the immune system, it is generally not recommended for use in pregnant or nursing women unless the potential benefit outweighs the potential risk, as assessed by the treating physician.
How do I order Korjuny from GNH USA?+
To place an order, visit the product page for Korjuny on gnh-usa.com and submit an enquiry with the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.
How does Korjuny compare with other treatments for malignant ascites?+
Korjuny’s bispecific antibody mechanism differs from conventional chemotherapy or paracentesis by directly engaging the patient’s immune system to target EpCAM‑positive tumor cells. While other intraperitoneal agents may rely on cytotoxic effects, catumaxomab offers a targeted immunotherapeutic approach, which can result in different efficacy and safety profiles.
What are the storage and handling requirements for Korjuny?+
Korjuny should be stored refrigerated at 2‑8 °C. It must be kept in its original container, protected from light, and should never be frozen or shaken. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.
How is Korjuny administered?+
Korjuny is given as an intraperitoneal infusion. The solution is administered directly into the peritoneal cavity, typically by a trained healthcare professional in a clinical setting, following the dosing schedule prescribed by the oncologist.
What are the most serious risks associated with Korjuny?+
Serious risks include hypersensitivity reactions such as anaphylaxis, cytokine release syndrome, severe infections, hepatic toxicity, and neutropenia. Patients should be closely monitored during and after infusion for any signs of these adverse events, and appropriate medical intervention should be available.
Who should not use Korjuny?+
Korjuny is contraindicated in patients with known hypersensitivity to catumaxomab or any murine protein components, those with active uncontrolled infections, and individuals receiving live vaccines. Caution is also advised for patients with severe hepatic impairment or existing severe immune disorders.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Catumaxomab
Route
Intraperitoneal Use
Manufacturer
Atnahs Pharma Netherlands B.V.
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU